The most common haematological adverse events of grade @ or higher were leucopenia ( @ -LSB- @ % -RSB- of @ patients given mFOLFOX@ plus bevacizumab included in safety analysis vs six -LSB- @ % -RSB- of @ given SOX plus bevacizumab ; p = @ ) and neutropenia ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ; p < @ ) .